Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...
The report is the latest indictment of America’s broken healthcare system.
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
During a roughly five-year span, CVS Health, Cigna, and UnitedHealth benefited the most from increasing prices for generic drugs that treated illnesses such as HIV and cancer. Some of the price hikes ...
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
Margin expansion at Express Scripts, Caremark and Optum Rx increased by $336 million between 2017 and 2021, officials say.
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
The Federal Trade Commission said in its second interim staff report on prescription-drug middlemen that the "significant markups" in prices above what the drugs cost generated an extra $7.3 billion ...
Three major drug middlemen needlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback